Emergent Net Working Capital vs Long Term Debt Analysis

EBS Stock  USD 10.11  0.08  0.80%   
Emergent Biosolutions financial indicator trend analysis is much more than just examining Emergent Biosolutions latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Emergent Biosolutions is a good investment. Please check the relationship between Emergent Biosolutions Net Working Capital and its Long Term Debt accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Emergent Biosolutions. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
For more information on how to buy Emergent Stock please use our How to Invest in Emergent Biosolutions guide.

Net Working Capital vs Long Term Debt

Net Working Capital vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Emergent Biosolutions Net Working Capital account and Long Term Debt. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Emergent Biosolutions' Net Working Capital and Long Term Debt is 0.41. Overlapping area represents the amount of variation of Net Working Capital that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of Emergent Biosolutions, assuming nothing else is changed. The correlation between historical values of Emergent Biosolutions' Net Working Capital and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Working Capital of Emergent Biosolutions are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Net Working Capital i.e., Emergent Biosolutions' Net Working Capital and Long Term Debt go up and down completely randomly.

Correlation Coefficient

0.41
Relationship DirectionPositive 
Relationship StrengthWeak

Net Working Capital

Long Term Debt

Long-term debt is a debt that Emergent Biosolutions has held for over one year. Long-term debt appears on Emergent Biosolutions balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Emergent Biosolutions balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.
Most indicators from Emergent Biosolutions' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Emergent Biosolutions current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Emergent Biosolutions. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
For more information on how to buy Emergent Stock please use our How to Invest in Emergent Biosolutions guide.At this time, Emergent Biosolutions' Selling General Administrative is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 8.8 M in 2024, whereas Tax Provision is likely to drop slightly above 48.4 M in 2024.
 2021 2022 2023 2024 (projected)
Total Operating Expenses640.9M593.2M1.0B1.1B
Cost Of Revenue757.5M693.7M705.4M740.7M

Emergent Biosolutions fundamental ratios Correlations

0.880.510.550.950.740.650.510.60.740.740.430.440.740.620.650.770.580.630.770.730.920.640.420.70.69
0.880.510.810.730.670.890.270.590.60.730.730.370.60.520.70.60.540.770.70.670.990.590.70.750.71
0.510.510.590.390.820.370.690.90.460.790.59-0.390.460.630.750.00.720.790.88-0.050.540.910.30.710.77
0.550.810.590.370.630.740.230.560.460.620.910.030.460.250.560.160.310.790.610.280.730.610.940.60.61
0.950.730.390.370.670.430.550.440.80.580.220.530.80.530.460.820.440.490.690.770.790.550.260.510.49
0.740.670.820.630.670.470.840.840.610.920.52-0.230.610.740.790.270.770.810.830.160.690.960.390.810.79
0.650.890.370.740.430.47-0.030.510.170.650.760.240.170.530.720.40.530.740.450.540.870.380.640.770.73
0.510.270.690.230.550.84-0.030.650.610.690.09-0.340.610.550.480.080.620.420.67-0.110.320.830.010.50.47
0.60.590.90.560.440.840.510.650.360.910.65-0.370.360.80.920.120.870.860.860.050.630.910.250.870.92
0.740.60.460.460.80.610.170.610.360.410.270.391.00.170.210.560.230.380.720.490.610.590.390.250.23
0.740.730.790.620.580.920.650.690.910.410.6-0.250.410.840.940.240.90.840.780.170.760.890.360.970.93
0.430.730.590.910.220.520.760.090.650.270.6-0.090.270.320.650.050.40.850.580.220.680.570.780.630.67
0.440.37-0.390.030.53-0.230.24-0.34-0.370.39-0.25-0.090.39-0.21-0.260.77-0.34-0.16-0.010.880.38-0.350.19-0.2-0.2
0.740.60.460.460.80.610.170.610.361.00.410.270.390.170.210.560.230.380.720.490.610.590.390.250.23
0.620.520.630.250.530.740.530.550.80.170.840.32-0.210.170.880.330.910.70.590.220.60.7-0.040.850.85
0.650.70.750.560.460.790.720.480.920.210.940.65-0.260.210.880.230.930.860.730.190.740.790.280.980.98
0.770.60.00.160.820.270.40.080.120.560.240.050.770.560.330.230.170.230.390.90.640.150.160.240.27
0.580.540.720.310.440.770.530.620.870.230.90.4-0.340.230.910.930.170.710.670.060.610.780.00.910.86
0.630.770.790.790.490.810.740.420.860.380.840.85-0.160.380.70.860.230.710.80.280.780.820.550.840.87
0.770.70.880.610.690.830.450.670.860.720.780.58-0.010.720.590.730.390.670.80.320.740.890.370.70.76
0.730.67-0.050.280.770.160.54-0.110.050.490.170.220.880.490.220.190.90.060.280.320.70.030.30.230.23
0.920.990.540.730.790.690.870.320.630.610.760.680.380.610.60.740.640.610.780.740.70.610.590.780.74
0.640.590.910.610.550.960.380.830.910.590.890.57-0.350.590.70.790.150.780.820.890.030.610.340.760.79
0.420.70.30.940.260.390.640.010.250.390.360.780.190.39-0.040.280.160.00.550.370.30.590.340.350.35
0.70.750.710.60.510.810.770.50.870.250.970.63-0.20.250.850.980.240.910.840.70.230.780.760.350.96
0.690.710.770.610.490.790.730.470.920.230.930.67-0.20.230.850.980.270.860.870.760.230.740.790.350.96
Click cells to compare fundamentals

Emergent Biosolutions Account Relationship Matchups

Emergent Biosolutions fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets2.3B2.9B3.0B3.2B1.8B1.2B
Short Long Term Debt Total811.3M874.8M841M1.4B860.2M903.2M
Total Stockholder Equity1.1B1.4B1.6B1.4B649.3M621.9M
Net Debt643.5M253.5M264.9M763.2M748.5M785.9M
Cash167.8M621.3M576.1M642.6M111.7M217.0M
Other Assets65.6M115M57.3M191.3M220.0M231.0M
Cash And Short Term Investments167.8M621.3M576.1M642.6M111.7M217.2M
Common Stock Shares Outstanding52.4M53.8M54.1M50.1M51.2M41.4M
Liabilities And Stockholders Equity2.3B2.9B3.0B3.2B1.8B1.2B
Other Current Assets20.6M73.2M70.4M57.9M47.9M25.8M
Other Stockholder Equity676.5M745.3M677.2M645.8M676.7M710.5M
Total Liab1.2B1.4B1.3B1.8B1.2B1.2B
Other Liab199.9M210.7M156.8M90.4M104.0M66.7M
Current Deferred Revenue101.9M131.5M140.4M26.4M30.4M28.1M
Long Term Debt798.4M841M809.4M448.5M446.5M290.2M
Property Plant And Equipment Gross542.3M644.1M800.1M817.6M794.2M833.9M
Accumulated Other Comprehensive Income(9.9M)(25.3M)(16.1M)3.1M(5.7M)(6.0M)
Property Plant Equipment542.3M644.1M800.1M817.6M940.2M987.3M
Retained Earnings Total Equity421.8M726.9M957.8M734M844.1M440.2M
Deferred Long Term Liab63.9M53.2M94.9M71.8M82.6M86.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Emergent Stock Analysis

When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.